Crossref journal-article
Springer Science and Business Media LLC
Nature Medicine (297)
Bibliography

Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999). Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine, 5(3), 347–350.

Authors 10
  1. Peter Klivenyi (first)
  2. Robert J. Ferrante (additional)
  3. Russell T. Matthews (additional)
  4. Mikhail B. Bogdanov (additional)
  5. Autumn M. Klein (additional)
  6. Ole A. Andreassen (additional)
  7. Gerald Mueller (additional)
  8. Marieke Wermer (additional)
  9. Rima Kaddurah-Daouk (additional)
  10. M. Flint Beal (additional)
References 23 Referenced 537
  1. Wong, P.C. et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14, 1105–1116 (1995). (10.1016/0896-6273(95)90259-7) / Neuron by PC Wong (1995)
  2. Gurney, M.E. et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772–1775 (1994). (10.1126/science.8209258) / Science by ME Gurney (1994)
  3. Carri, M.T. et al. Expression of a Cu,Zn superoxide dismutase typical of familial amyotrophic lateral sclerosis induces mitochondrial alteration and increase of cytosolic Ca2+ concentration in transfected neuroblastoma SH-SY5Y cells. FEBS Lett. 414, 365–368 (1997). (10.1016/S0014-5793(97)01051-X) / FEBS Lett. by MT Carri (1997)
  4. Hemmer, W. & Wallimann, T. Functional aspects of creatine kinase in brain. Dev. Neurosci. 15, 249–260 (1993). (10.1159/000111342) / Dev. Neurosci. by W Hemmer (1993)
  5. O'Gorman, E., Beutner, G., Wallimann, T. & Brdiczka, D. Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain. Biochim. Biophys. Acta 1276, 161–170 (1996). (10.1016/0005-2728(96)00074-6) / Biochim. Biophys. Acta by E O'Gorman (1996)
  6. Gurney, M.E. et al. Antioxidants and inhibitors of glutamatergic transmission have therapeutic benefit in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39, 147–157 (1996). (10.1002/ana.410390203) / Ann. Neurol. by ME Gurney (1996)
  7. Dugan, L.L. et al. Carboxyfullerenes as neuroprotective agents. Proc. Natl. Acad. Sci. USA 94, 9434–9439 (1997). (10.1073/pnas.94.17.9434) / Proc. Natl. Acad. Sci. USA by LL Dugan (1997)
  8. Hottinger, A.F., Fine, E.G., Gurney, M.E., Zurn, A.D. & Aebischer, P. The copper chelator d-penicillamine delays onset of disease and extends survival in a transgenic moouse model of familial amyotrophic lateral sclerosis. Eur. J. Neurosci. 9, 1548–1551 (1997). (10.1111/j.1460-9568.1997.tb01511.x) / Eur. J. Neurosci. by AF Hottinger (1997)
  9. Kostic, V. et al. Midbrain dopaminergic neuronal degeneration in a transgenic mouse model of familial amyotrophic lateral sclerosis. Ann. Neurol. 41, 497–504 (1997). (10.1002/ana.410410413) / Ann. Neurol. by V Kostic (1997)
  10. Ferrante, R.J. et al. Increased 3-nitrotyrosine and oxidative damage in mice with a human Cu, Zn superoxide dismutase mutation. Ann. Neurol. 42, 326–334 (1997). (10.1002/ana.410420309) / Ann. Neurol. by RJ Ferrante (1997)
  11. Bogdanov, M.B., Ramos, L.E., Xu, X. & Beal, M.F. Elevated "hydroxyl radical" generation in vivo in an animal model of amyotrophic lateral sclerosis. J. Neurochem. 71, 1321–1324 (1998). (10.1046/j.1471-4159.1998.71031321.x) / J. Neurochem. by MB Bogdanov (1998)
  12. Sasaki, S., Maruyama, S., Yamane, K., Sakuma, H. & Takeishi, M. Ultrastructure of swollen proximal axons of anterior horn neurons in motor neuron disease. J. Neurol. Sci. 97, 233–240 (1990). (10.1016/0022-510X(90)90221-8) / J. Neurol. Sci. by S Sasaki (1990)
  13. Siklos, L. et al. Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis. Ann. Neurol. 39, 203–219 (1996). (10.1002/ana.410390210) / Ann. Neurol. by L Siklos (1996)
  14. White, R.J. & Reynolds, I.J. Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure. J. Neurosci. 16, 5688–5697 (1996). (10.1523/JNEUROSCI.16-18-05688.1996) / J. Neurosci. by RJ White (1996)
  15. O'Gorman, E. et al. The role of creatine kinase inhibition of mitochondrial permeability transition. FEBS Lett. 414, 253–257 (1997). (10.1016/S0014-5793(97)01045-4) / FEBS Lett. by E O'Gorman (1997)
  16. Sauter, A. & Rudin, M. Determination of creatine kinase parameters in rat brain by NMR magnetization transfer: correlation with brain function. J. Biol. Chem. 268, 13166–13171 (1993). (10.1016/S0021-9258(19)38633-8) / J. Biol. Chem. by A Sauter (1993)
  17. Corbett, R.J.T. & Laptook, A.R. Age-related changes in swine brain creatine kinase-catalyzed 31P exchange measured in vivo using 31P NMR magnetization transfer. J. Cereb. Blood Flow Metab. 14, 1070–1077 (1994). (10.1038/jcbfm.1994.140) / J. Cereb. Blood Flow Metab. by RJT Corbett (1994)
  18. Xu, C.J. et al. Phosphocreatine-dependent glutamate uptake by synaptic vesicles. J. Biol. Chem. 271, 13435–13440 (1996). (10.1074/jbc.271.23.13435) / J. Biol. Chem. by CJ Xu (1996)
  19. Rothstein, J.D., M., V.K., Levey, A.I., Martin, L. & Kuncl, R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 38, 73–84 (1995). (10.1002/ana.410380114) / Ann. Neurol. by JD Rothstein (1995)
  20. Sipila, I., Rapola, J., Simell, O. & Vannas, A. Supplementary creatine as a treatment for gyrate atrophy of the choroid and retina. N. Engl. J. Med. 304, 867–870 (1981). (10.1056/NEJM198104093041503) / N. Engl. J. Med. by I Sipila (1981)
  21. Blanchard, V., Raisman-Vozari, R., Vyas, S., Michel, P.P., Javoy-Agid, F. & Uhl, G. Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of rat mesencephalon. Molec. Brain Res. 22, 29–40 (1994). (10.1016/0169-328X(94)90029-9) / Molec. Brain Res. by V Blanchard (1994)
  22. Matthews, R.T. et al. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. 18, 156–163 (1998). (10.1523/JNEUROSCI.18-01-00156.1998) / J. Neurosci. by RT Matthews (1998)
  23. Bogdanov, M.B., Ramos, L.E., Xu, X. & Beal, M.F. Elevated "hydroxyl radical" generation in vivo in an animal model of amyotrophic lateral sclerosis. J. Neurochem. 71, 1321–1324 (1998). (10.1046/j.1471-4159.1998.71031321.x) / J. Neurochem. by MB Bogdanov (1998)
Dates
Type When
Created 23 years, 1 month ago (July 26, 2002, 4:34 a.m.)
Deposited 2 years, 3 months ago (May 18, 2023, 6:13 p.m.)
Indexed 1 day, 4 hours ago (Aug. 26, 2025, 2:37 a.m.)
Issued 26 years, 5 months ago (March 1, 1999)
Published 26 years, 5 months ago (March 1, 1999)
Published Print 26 years, 5 months ago (March 1, 1999)
Funders 0

None

@article{Klivenyi_1999, title={Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis}, volume={5}, ISSN={1546-170X}, url={http://dx.doi.org/10.1038/6568}, DOI={10.1038/6568}, number={3}, journal={Nature Medicine}, publisher={Springer Science and Business Media LLC}, author={Klivenyi, Peter and Ferrante, Robert J. and Matthews, Russell T. and Bogdanov, Mikhail B. and Klein, Autumn M. and Andreassen, Ole A. and Mueller, Gerald and Wermer, Marieke and Kaddurah-Daouk, Rima and Beal, M. Flint}, year={1999}, month=mar, pages={347–350} }